Combination treatment with anti-LIF antibody (10 mg/kg twice a week) and gemcitabine (100 mg/kg once a week) was reported to result in complete tumor remissions in seven out of nine patient-xenograft mouse models (PDX), which was maintained after treatment withdrawal. The gene discussed is LIF; the disease is neoplasm.